

Indicators for monitoring and evaluation of the kala-azar elimination programme

August 2010

Bangladesh, India and Nepal

WHO Library Cataloguing-in-Publication Data

Indicators for monitoring and evaluation of the kala-azar elimination programme.

1.Leishmaniasis, Visceral - prevention and control. 2.Program evaluation - methods. 3.Indicators. 4.Mosquito control. 5.Bangladesh. 6.India. 7.Nepal. I.World Health Organization. II.UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases.

ISBN 978 92 4 150037 1

(NLM classification: WC 715)

Copyright © World Health Organization on behalf of the Special Programme for Research and Training in Tropical Diseases 2010

All rights reserved.

The use of content from this health information product for all non-commercial education, training and information purposes is encouraged, including translation, quotation and reproduction, in any medium, but the content must not be changed and full acknowledgement of the source must be clearly stated. A copy of any resulting product with such content should be sent to TDR, World Health Organization, Avenue Appia, 1211 Geneva 27, Switzerland. TDR is a World Health Organization (WHO) executed UNICEF/UNDP/World Bank/World Health Organization Special Programme for Research and Training in Tropical Diseases.

This information product is not for sale. The use of any information or content whatsoever from it for publicity or advertising, or for any commercial or income-generating purpose, is strictly prohibited. No elements of this information product, in part or in whole, may be used to promote any specific individual, entity or product, in any manner whatsoever.

The designations employed and the presentation of material in this health information product, including maps and other illustrative materials, do not imply the expression of any opinion whatsoever on the part of WHO, including TDR, the authors or any parties cooperating in the production, concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delineation of frontiers and borders.

Mention or depiction of any specific product or commercial enterprise does not imply endorsement or recommendation by WHO, including TDR, the authors or any parties cooperating in the production, in preference to others of a similar nature not mentioned or depicted.

The views expressed in this health information product are those of the authors and do not necessarily reflect those of WHO, including TDR. WHO, including TDR, and the authors of this health information product make no warranties or representations regarding the content, presentation, appearance, completeness or accuracy in any medium and shall not be held liable for any damages whatsoever as a result of its use or application. WHO, including TDR, reserves the right to make updates and changes without notice and accepts no liability for any errors or omissions in this regard. Any alteration to the original content brought about by display or access through different media is not the responsibility of WHO, including TDR, or the authors. WHO, including TDR, and the authors accept no responsibility whatsoever for any inaccurate advice or information that is provided by sources reached via linkages or references to this health information product.

Web version only.

Indicators for monitoring and evaluation of the kala-azar elimination programme

Kala-azar elimination in Bangladesh, India and Nepal

August 2010

Contents

Abbreviations	3
Introduction	4
PART 1. CASE DETECTION AND MANAGEMENT	5
1.1 Case definitions	5
1.1.1 Case definition of kala-azar (KA)	5
1.1.2 Treatment outcomes in KA	6
1.1.3 Case definition of post kala-azar dermal leishmaniasis (PKDL)	5
1.1.4 Treatment outcomes in PKDL	6
1.2 Definitions of KA case-detection activities	7
1.3 Key indicators for the KA elimination initiative	8
1.4 Monitoring clinical outcomes	9
1.5 Pharmacovigilance	9
1.6 Framework of indicators for monitoring and evaluation (M&E) of the KA elimination initiative	13
PART 2. VECTOR MANAGEMENT	19
2.1 Definitions and sources of information	19
2.1.1 Definitions	19
2.1.2 Sources of information	19
2.2 Key indicators for vector management	19
2.3 Framework of indicators for vector management	20
Acknowledgements	26
Bibliography	27
Glossary	28
Appendix 1: Pictorial for PKDL screening (macular and popular forms)	31
Appendix 2: M&E tool kit for vector control	32

Abbreviations

ACD	active case detection
ECG	electrocardiogram
HH	household
IEC	information, education and communication
IRS	indoor residual spraying
ITN	insecticide-treated net
IVM	integrated vector management
KA	kala-azar
LN	long-lasting insecticide-treated net
M&E	monitoring and evaluation
OR	operational research
PCD	passive case detection
PHC	primary health centre
PKDL	post kala-azar dermal leishmaniasis
PP	private practitioner
RDT	rapid diagnostic test
rK39	rK39 antigen
rK39RDT	rK39 antigen-based rapid diagnostic test
SAG	sodium antimony gluconate
SSS	slit-skin smear
UHC	upazila health centre
VL	visceral leishmaniasis

Introduction

This document contains the WHO Regional Office for South-East Asia's and The Special Programme for Research and Training in Tropical Diseases' (TDR) recommended indicators for monitoring and evaluation of the kala-azar elimination programme.

The document is presented in two parts:

- **Part 1** covers case detection and management.
- **Part 2** covers vector management.

The indicators outlined in this document were developed by representatives from Bangladesh, India and Nepal at a WHO-TDR sponsored workshop on kala-azar held in Dhaka, Bangladesh 8–16 June 2009 and were endorsed by the regional technical advisory committee (RTAG) in Dhaka, Bangladesh 7–10 December 2009.

Department of Communicable Diseases WHO Regional Office for South-East Asia World Health House Indraprastha Estate Mahatma Gandhi Marg New Delhi 110 002 India	Special Programme for Research and Training in Tropical Diseases World Health Organization Avenue Appia 20 1211 Geneva 27 Switzerland
--	--

We are grateful to The Federal Ministry for Economic Cooperation and Development (BMZ) and The Deutsche Gesellschaft für Technische Zusammenarbeit (GTZ) for their support and cooperation in the production of this document.

PART 1. CASE DETECTION AND MANAGEMENT

Kala-azar (KA), also known as visceral leishmaniasis (VL), is an infectious disease caused by the *Leishmania* parasite when it is transmitted by the bite of an infected sandfly. KA is fatal when untreated. There are approximately 500 000 new cases every year worldwide, the majority of which occur in Bihar, India, followed by the border regions of Bangladesh and Nepal. These figures do not reflect the true social impact of this disease because KA has a focal distribution that affects primarily the poorest communities.

Although no vaccine is available, important recent advances have made it possible to eliminate KA from the Indian subcontinent. This document provides definitions and indicators that will be useful for those involved in KA elimination.

1.1 Case definitions

1.1.1 Case definition of KA

A person from an endemic area with a fever of more than two weeks duration and with splenomegaly should be tested for KA:

- using a standard, quality-assured rapid diagnostic test (RDT) based on the rK39 antigen at the primary health centre (PHC)/upazila health centre (UHC) level
- or
- by biopsy for parasitology at hospitals with appropriate training.

These are the case definitions presented in the country guidelines of Bangladesh, India and Nepal; the elimination initiative documents use only one case definition for KA (see Box 1).

Box 1. Case definition of KA

A case of KA is defined as: a person from an endemic area with fever of more than two weeks duration and with splenomegaly, who is confirmed by an RDT or a biopsy

1.1.2 Treatment outcomes in KA

Treatment outcomes in KA have to be assessed twice:

- (i) at the last day of drug treatment (initial outcome)
- and
- (ii) six months after the last drug was taken (final outcome).

The KA elimination initiative has trained health workers to distinguish four main outcomes in KA treatment (see Box 2).

Box 2. Treatment outcomes in KA

1. **Cure:** *a patient is considered clinically cured if he/she has completed full treatment and there are no signs and symptoms of KA*
2. **Non-response:** *signs and symptoms persist or recur despite satisfactory treatment for more than two weeks*
3. **Relapse:** *any reappearance of KA signs and symptoms within a period of six months after the end of treatment*
4. **Treatment failure:** *non-response or relapse*

There are more possible outcomes at each time point. These are listed below.

At initial assessment, at the last day of drug treatment

- **Initial cure:** a full course of drugs has been completed AND the patient has clinically improved. Clinical criteria for cure should be assessed as no fever + regression of enlarged spleen + return of appetite and/or gain in body weight.
- **Non-response:** signs and symptoms persist or recur. Switch to a second-line drug because of no response to the first-line drug.
- **Side-effects related switch:** side-effects necessitate a change of treatment.
- **Death:** any death, whether or not related to KA.
- **Default:** the patient does not complete treatment and/or does not present for assessment after treatment.

At final assessment, six months after the last drug taken

- **Final cure:** an initial cure patient who is symptom-free at six months after the end of treatment.
- **Relapse:** any reappearance of KA symptoms within a period of six months after the end of treatment.
- **Death:** any death, whether or not related to KA.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_28915

